Valuation dashboard for Agilent Technologies, Inc. (A) with P/E 34.42, P/B 6.70, EV/EBITDA 25.3 and dividend yield 0.58%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS).
What would it be worth at its usual multiples?
Versus its usual multiples: fairly priced · Current P/E 34.4× · Multiples range: $155.91 · $164.74.
At the decade median (32.4×) $165 (-6 %); at its sector median (30.7×) $156 (-11 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Agilent Technologies, Inc. reported revenue of $6.95B in the most recent fiscal year, growing at a 5-year CAGR of 5.4%. Net income reached $1.30B, with a 12.6% 5-year CAGR.
Trailing-twelve-month margins: gross margin 53.7%, operating margin 22.2%, net margin 19.5%.
At $174.87 (closing price, October 30, 2026), A trades at a P/E of 34.42 and an ROE of 20.47%. Market capitalisation stands at $49.3B, placing it among large-cap names.
Balance sheet quality for A: debt-to-equity ratio of 0.54, current ratio of 2.05 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 34.42 |
| Price / Book | 6.70 |
| EV / EBITDA | 25.3 |
| Dividend Yield | 0.58% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| A | Agilent Technologies, Inc. | $49.3B | 34.42 | 6.70 | 20.5% |
| BRKR | Bruker Corporation | $8.7B | 3.62 | -2.9% | |
| TMO | Thermo Fisher Scientific Inc. | $257.7B | 36.76 | 4.71 | 13.3% |
| DHR | Danaher Corporation | $163.3B | 38.01 | 3.05 | 8.2% |
| MTD | Mettler-Toledo International Inc. | $33.6B | 37.70 | 2,628.07 | -12.0% |
| WAT | Waters Corporation | $45.4B | 115.39 | 2.99 | 1.9% |
| RVTY | Revvity, Inc. | $17.5B | 74.76 | 2.43 | 3.3% |
| QGEN | Qiagen N.V. | $10.3B | 25.75 | 3.09 | 11.6% |
Price
| Price | $174.87 (closing price, October 30, 2026) |
| Market Cap | $49.3B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 20.47% |
| Return on Invested Capital | 11.88% |
| Return on Assets | 10.31% |
| Gross Margin | 53.73% |
| Operating Margin | 22.23% |
| Net Margin | 19.53% |
Related companies: BRKR · TMO · DHR · MTD · WAT · RVTY · QGEN · BIO
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of A: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks